GeneOne Life Science Statistics
Total Valuation
KRX:011000 has a market cap or net worth of KRW 231.25 billion. The enterprise value is 257.48 billion.
Market Cap | 231.25B |
Enterprise Value | 257.48B |
Important Dates
The last earnings date was Wednesday, May 14, 2025.
Earnings Date | May 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
KRX:011000 has 84.71 million shares outstanding. The number of shares has increased by 2.34% in one year.
Current Share Class | 84.71M |
Shares Outstanding | 84.71M |
Shares Change (YoY) | +2.34% |
Shares Change (QoQ) | -0.29% |
Owned by Insiders (%) | 10.01% |
Owned by Institutions (%) | 4.46% |
Float | 76.23M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 6.22 |
PB Ratio | 3.03 |
P/TBV Ratio | 3.04 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -5.38 |
EV / Sales | 6.92 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -15.66 |
Financial Position
The company has a current ratio of 0.63, with a Debt / Equity ratio of 0.40.
Current Ratio | 0.63 |
Quick Ratio | 0.21 |
Debt / Equity | 0.40 |
Debt / EBITDA | n/a |
Debt / FCF | -1.84 |
Interest Coverage | -15.25 |
Financial Efficiency
Return on equity (ROE) is -50.42% and return on invested capital (ROIC) is -21.49%.
Return on Equity (ROE) | -50.42% |
Return on Assets (ROA) | -17.31% |
Return on Invested Capital (ROIC) | -21.49% |
Return on Capital Employed (ROCE) | -40.84% |
Revenue Per Employee | 885.53M |
Profits Per Employee | -1.14B |
Employee Count | 42 |
Asset Turnover | 0.25 |
Inventory Turnover | 2.93 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.26% in the last 52 weeks. The beta is 0.93, so KRX:011000's price volatility has been similar to the market average.
Beta (5Y) | 0.93 |
52-Week Price Change | +20.26% |
50-Day Moving Average | 2,389.12 |
200-Day Moving Average | 2,413.27 |
Relative Strength Index (RSI) | 47.98 |
Average Volume (20 Days) | 6,767,948 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:011000 had revenue of KRW 37.19 billion and -47.89 billion in losses. Loss per share was -600.52.
Revenue | 37.19B |
Gross Profit | -10.53B |
Operating Income | -41.01B |
Pretax Income | -48.15B |
Net Income | -47.89B |
EBITDA | -22.85B |
EBIT | -41.01B |
Loss Per Share | -600.52 |
Balance Sheet
The company has 3.94 billion in cash and 30.17 billion in debt, giving a net cash position of -26.23 billion or -309.61 per share.
Cash & Cash Equivalents | 3.94B |
Total Debt | 30.17B |
Net Cash | -26.23B |
Net Cash Per Share | -309.61 |
Equity (Book Value) | 76.38B |
Book Value Per Share | 956.75 |
Working Capital | -16.26B |
Cash Flow
In the last 12 months, operating cash flow was -13.18 billion and capital expenditures -3.26 billion, giving a free cash flow of -16.44 billion.
Operating Cash Flow | -13.18B |
Capital Expenditures | -3.26B |
Free Cash Flow | -16.44B |
FCF Per Share | -194.07 |
Margins
Gross margin is -28.31%, with operating and profit margins of -110.25% and -128.77%.
Gross Margin | -28.31% |
Operating Margin | -110.25% |
Pretax Margin | -129.48% |
Profit Margin | -128.77% |
EBITDA Margin | -61.45% |
EBIT Margin | -110.25% |
FCF Margin | n/a |
Dividends & Yields
KRX:011000 does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -2.34% |
Shareholder Yield | n/a |
Earnings Yield | -20.71% |
FCF Yield | -7.11% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on December 3, 2021. It was a forward split with a ratio of 1.5.
Last Split Date | Dec 3, 2021 |
Split Type | Forward |
Split Ratio | 1.5 |
Scores
KRX:011000 has an Altman Z-Score of -1.8. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -1.8 |
Piotroski F-Score | n/a |